CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2005-10-05): EU OKs briefer Schering-Plough hepatitis C therapy


EU OKs briefer Schering-Plough hepatitis C therapy

Last Updated: 2005-10-05 14:33:39 -0400 (Reuters Health)

NEW YORK (Reuters) - Schering-Plough Corp. on Wednesday said European regulators approved a 24-week course of treatment with its combination therapy for some patients infected with the most common form of hepatitis C, rather than the standard 48-week regimen.

The company said the European Commission approved the shorter treatment for a "subgroup" of patients with low bloodstream levels of the genotype 1 form of the virus, whose virus levels then fall to undetectable levels during the first four weeks of treatment.

"This is the only treatment regimen approved in the European Union for a 24-week course of therapy in certain genotype 1 patients," the Kenilworth, New Jersey-based company said in a release.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.